30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q13 Revenue: ArthroCare

$60.3MM, +6%

  • Sports Medicine $58MM, +6% (Americas 5%, ex-U.S. +12%; Americas proprietary products +8%)
  • Other (includes spine) $2.2MM, +20%


  • Proprietary Sports Medicine growth attributed to higher Coblation sales in hip, knee, shoulder, partially offset by -2% ASP
  • Coblation customer base increased in number of customers and revenue per customer
  • Sports Medicine sales to distributor markets increased, notably to Asia Pacific and southern Europe
  • Made a small investment in OrthoSpace and obtained distribution rights to InSpace in certain ex-U.S. markets, for the treatment of pain associated with rotator cuff tears
  • To date, >150 surgeons participated in arthroscopic knee education campaign
  • New Coblation platform slated to undergo initial clinical evaluation ex-U.S. in 1H14, to focus on energy platform that can deliver operating modes specifically designed for knee tissue
  • Q-Fix products from Eleven Blade acquisition expected to launch in early 2014
  • No update yet to settlement with Dept. of Justice relative to DiscoCare